INTRODUCTION
============

*Fusarium* infections are a major challenge with respect to the diagnosis and treatment, especially in neutropenic patients. Disseminated infections may be fatal and are a considerable source of increased healthcare costs. A major area of concern is the intrinsic resistance to a broad range of antifungals,^[@bib1]^ which is a characteristic of *Fusarium*. During the past decade, the *F. solani* complex has received special interest because of the increasing numbers of infections worldwide.^[@bib2]^ More than 300 cases of *Fusarium* keratitis were associated with contaminated contact lens cleaning solution, causing outbreaks between 2005 and 2007, where members of the *F*. *solani* species complex played a major role.^[@bib3]^ Furthermore, reservoirs of infectious *Fusarium* species in hospital environments, especially plumbing and water systems, have been reported.^[@bib4]^

Although human fusariosis was only recognized since the late 1950s and endemic areas are mostly located in tropical and subtropical countries,^[@bib5]^ their global significance has only recently come into focus within the past three decades. Etiological agents differ in antifungal susceptibility,^[@bib6]^ virulence profiles, geographic distribution, ecological niches, life cycle, host and mycotoxin production.^[@bib7]^ Although agents of fusariosis are mostly environmental,^[@bib8]^ the potential of nosocomial transmission has recently been raised,^[@bib9]^ especially with reference to the high mortality rate of \~90% in patients with prolonged and severe neutropenia.^[@bib10]^

The burden of disease has not been established, but numerous clinical case series and case reports provide an estimate of the magnitude of the problem. Most published studies have focused on prevalence in single healthcare centers.^[@bib10],\ [@bib11],\ [@bib12],\ [@bib13],\ [@bib14],\ [@bib15],\ [@bib16]^ Nucci *et al.*^[@bib17]^ reported 233 cases from different hospitals on a global scale. Mohammed *et al.*^[@bib18]^ reported 26 cases from the United States and reviewed 97 cases from the literature, and Horn *et al.*^[@bib12]^ described 65 cases from the North American Path Alliance Registry. A major problem in comparative studies is the subdivision of the classical species into a series of molecular siblings, which renders the older literature without sequence data uninterpretable. Despite the current clinical importance of the organism, the phylogenetic relationships among species, varieties and geographical groups in *Fusarium* are currently elusive. Hence, the re-interpretation of these data in the light of modern molecular phylogeny is compulsory.

Molecular phylogenetic studies have led to the description of many *Fusarium* species with clinical relevance. These include members of the *F. solani* species complex, namely, *F. falciforme*, *F. keratoplasticum*, *F. lichenicola*, *F. petroliphilum*, *F. pseudensiforme* and *F. solani* (FSSC5), which is also known as *Fusisporium solani* and *Fusarium* haplotype '6\'. The *F. oxysporum* species complex (FOSC) contains three lineages, which are involved in fusariosis and still have not been formally introduced as taxonomic species. The *F. fujikuroi* species complex includes *F. acutatum*, *F. ananatum*, *F. anthophilum*, *F. andiyazi*, *F. fujikuroi s.s.*, *F. globosum*, *F. guttiforme*, *F. musae*, *F. napiforme*, *F. nygamai*, *F. verticillioides*, *F. proliferatum*, *F. ramigenum*, *F. sacchari*, *F. subglutinans*, *F. temperatum* and *F. thapsinum*. Although rare, species of other *Fusarium* lineages are emerging as potential opportunistic pathogens, for example, in the *F. incarnatum-equiseti* species complex (FIESC; *F. incarnatum* and *F. equiseti*), the *F. dimerum* species complex (*F. dimerum*, *F. delphiniodes* and *F. penzigii*), the *F. chlamydosporum* species complex, the *F. sambucinum* species complex (*F. armeniacum*, *F. brachygibbosum*, *F. langsethiae* and *F. sporotrichioides*) and the *F. tricictum* species complex (*F. acuminatum* and *F. flocciferum*).^[@bib1]^

Over the past decade, the number of cases of fusariosis has increased worldwide, but there are only a few reports describing the molecular epidemiology; therefore, the aim of the present study is to introduce a hypothetical system that permits the interpretation and use of at least a part of the literature where sequence data are lacking. Pre-molecular publications, which include interpretable case reports and geographical information, were collected. Subsequently, available *Fusarium* strains that were collected worldwide and deposited during the past century in the CBS-KNAW, Fungal Biodiversity Centre, culture collection Utrecht, The Netherlands, were sequenced and re-identified with current diagnostic technology, which enables the phylogenetic analysis of the human--pathogenic *Fusarium* species. These data were then compared with published materials and their distribution with the assumption that their distributions in each region had remained unaltered.

MATERIALS AND METHODS
=====================

Fungal strains
--------------

A total of 127 strains collected from clinical samples (*n*=74; 58.3% collected between 1978 and 2015) and strains collected from the environment (*n*=53; 41.7% collected between 1929 and 2015) were analyzed. All of the strains were maintained under the name '*Fusarium*\' in the reference collection of CBS-KNAW, Utrecht, the Netherlands. The data regarding geographic origins and sources of isolation are listed in [Table 1](#tbl1){ref-type="table"}. All of the available type strains were included. Stock cultures were maintained on slants of 2% malt extract agar at 24 °C. The strains were assigned to a clinical subgroup and an environment subgroup.

DNA extraction
--------------

DNA was extracted following the Quick Cetyl trimethylammonium bromide (CTAB) protocol. A total of 1--10 mm^3^ fungal material was transferred to 2- mL screw-capped tubes prefilled with 490 μL 2 × CTAB buffer and 6--10 acid-washed glass beads. A total of 10 μL of proteinase K was added and mixed thoroughly on a MoBio vortex (MO BIO Laboratories, Inc., Carlsbad, CA, USA) for 10 min. Then, 500 μL of chloroform:isoamylalcohol (24:1) was added and shaken for 2 min after incubation for 60 min at 60 °C. The tubes were centrifuged for 10 min at 14 000 rpm, and the supernatant was collected in a new Eppendorf tube. To \~400 μL of the DNA sample, 2/3 vol (\~270 μL) of ice-cold isopropanol was added and centrifuged again at 14 000 rpm for 10 min, and the upper layer was dissolved in 1 mL ice-cold 70% ethanol. The tubes were centrifuged again at 14 000 rpm for 2 min, air-dried and resuspended in 50 μL TE buffer. The quality of the genomic DNA was verified by running 2--3 μL on a 0.8% agarose gel. Then, the DNA was quantified with a NanoDrop 2000 spectrophotometer (Thermo Fisher, Wilmington, DE, USA), and the samples were stored at −20 °C until ready for analysis.

DNA amplification and sequencing
--------------------------------

The following two gene regions were amplified directly from the genomic DNA: the second largest subunit of RNA polymerase (*RPB2*; Reeb *et al.*^[@bib19]^) and the translation elongation factor-1α (*TEF1α* O\'Donnell *et al.*^[@bib20]^) were amplified and sequenced following the methods published by Saleh *et al.*^[@bib16]^ The PCR reactions were performed in a volume of 12.5 μL containing 1.25 μL of 10 × PCR buffer, 7.5 μL of water, 0.5 μL of dNTP mix (2.5 mM), 0.25 μL of each primer (10 pmol), 0.05 μL of Taq polymerase (5 U/μL), 0.7 μL of dimethylsulphoxide and 1 μL of template DNA (100 ng/μL). The amplification was performed with the ABI Prism 2720 thermal cycler (Applied Biosystems, Foster City, CA, USA). The cycling conditions included 1 cycle of 5 min at 94 °C, 10 cycles of 45 s at 94 °C, 45 s at 55 °C and 1.5 min at 72 °C, 30 cycles of 45 s at 94 °C, 45 s at 52 °C and 1.30 min at 72 °C, a post elongation step of 6 min at 72 °C for *TEF1* (EF1, EF2) and a pre-denaturation for 3 min at 95 °C, 5 cycles of 45 s at 95 °C, 45 s at 58 °C and 2 min at 72 °C, 5 cycles of 45 s at 95 °C, 45 s at 56 °C and 2 min at 72 °C, 30 cycles of 45 s at 95 °C, 45 s at 52 °C and 2 min at 72 °C, and a post elongation step of 8 min at 72 °C for *RPB2* (5F2 and 7cr). The PCR products were visualized by electrophoresis on 1% (w/v) agarose gels. The sequencing PCR was performed as follows: 1 min at 95 °C followed by 30 cycles consisting of 10 s at 95 °C, 5 s at 50 °C and 2 min 60 °C. The reactions were purified with Sephadex G-50 fine (GE Healthcare Bio-Sciences, Uppsala, Sweden), and the sequencing was conducted on an ABI 3730xL automatic sequencer (Applied Biosystems) with a BigDye v3.1 terminator cycle sequencing kit (Applied Biosystems).

Identification
--------------

The strains were identified by BLAST in GenBank, *Fusarium* MLST (<http://www.cbs.knaw.nl/fusarium/>)^[@bib20]^ and the FUSARIUM-ID (<http://isolate.fusariumdb.org/>)^[@bib21]^ databases. In addition, the phylogenetic placements with species/haplotypes within species complexes were verified with available databases that are specific for *Fusarium*.

Phylogenetic analyses
---------------------

Sequences of *TEF1* and *RPB2* were undertaken to extend the genetic characterization of 127 isolates of *Fusarium* species previously characterized in terms of morphological characteristics. The sequences were edited using SeqMan in the Lasergene package (DNAstar, Madison, WI, USA). A phylogenetic approach was used to investigate the relationship between 65 strains of *Fusarium* species including type and reference strains. The sequences were aligned using MAFFT v. 7.127 (<http://mafft.cbrc.jp>) followed by manual adjustments with MEGA v. 6.2.^[@bib22]^ A combined alignment was constructed for *RPB2* and *TEF1* for both the reference and test strains. The best-fit model of evolution was determined by MEGA v. 6.2.^[@bib22]^ A bootstrapped maximum-likelihood analysis was performed using RAxMLVI-HPC v. 7.0.3^[@bib23]^ as implemented on the Cipres portal (<http://www.phylo.org/>),^[@bib24]^ with non-parametric bootstrapping using 1000 replicates. Detailed analyses of medically important strains were compared in relation with their clinical cases. For instance, *F. solani* actually represents a complex (that is, the *F. solani* species complex).

AFLP
----

The *Fusarium* strains were subjected to amplified fragment length polymorphism (AFLP) genotyping using a previously described method.^[@bib25]^ However, for the amplification of the DNA fragments, the selective residues (underlined) of the HpyCH4IV-primer (5′-GAT GAG TCC TGA CTA ATG AG-3′) and MseI-primer (5′-Flu-GTA GAC TGC GTA CCC GTAC-3′ MseI-C-selective primer) were replaced. The amplicons were diluted 20 × with double-distilled H~2~O (ddH~2~O); 1 μL of the diluted amplicon was then added to a mixture of 8.9 μL ddH~2~O and 0.1 μL LIZ600 (Applied Biosystems) followed by a heating step for 1 min at 100 °C and cooling to 4 °C. The AFLP fragment analysis was conducted using an ABI3500xL Genetic Analyzer (Applied Biosystems) according to the manufacturer\'s instructions. The raw data were then inspected visually after importation into BioNumerics v7.5 (Applied Maths, Sint Martens-Latem, Belgium) and analyzed by an Unweighted Pair Group Method with Arithmetic Mean clustering using the Pearson correlation coefficient. The analysis was restricted to DNA fragments in the range of 40--400 bp. The final AFLP dendrograms were based on the combination of sequencing and the AFLP data of both dendrograms.

Meta-analysis
-------------

The authors analyzed the existing medical literature on human cases of fusariosis from 1958 until December 2015. The authors conducted a systematic literature search using PubMed, and the terms '*Fusarium\'* and 'fusariosis\' were used for the search and both were also used as MeSH words and free words. Studies were only included that reported data for the individual cases because data provided in aggregate often lacked specific information for individual cases. Only cases with either histologically or culturally proven *Fusarium* infection were included. A total of 388 case reports in \~265 published studies were collected on a worldwide basis. The numbers are approximate because some cases have been used in repeated publications. Only cases with either histologically or culturally proven *Fusarium* infection were included ([Supplementary Reference S1](#sup1){ref-type="supplementary-material"}).

RESULTS
=======

Types of articles
-----------------

A total of 388 cases of fusariosis from 1958 until December 2015 were used in the literature data analysis. This included articles that were mostly single case reports, two patient cases and a series of cases of fusariosis. The reported cases of fusariosis were identified from all over the world, and particularly from tropical and subtropical countries with a large agrarian population such as Brazil, China, Colombia, India and Mexico. The other areas with frequent fusariosis were Australia, South Africa, Turkey and the Americas. *Fusarium* infections have also been reported from different countries in eastern and western Europe.

### Patient characteristics

An overview of the cases of fusariosis published in the medical literature, which includes the great majority of cases published to date, is provided in [Table 2](#tbl2){ref-type="table"}. The majority of patients were male (*n*=253; 65.2% mean 41 years; range three months--83 years). Over a third of the patients (*n*=143; 36.9%) had various underlying conditions at the time when the *Fusarium* infection was diagnosed. Causes of immunosuppression were hematological diseases and hematologic malignancies (*n*=122; 31.4%) and cancer of the solid organs (*n*=17; 4.8%). Other causes of immunosuppression were medication (*n*=140; 36%), which included antibiotic (*n*=34; 8.8%) and steroid treatment (*n*=10; 2.6%). Pathogen introduction was ranked as trauma (*n*=18; 4.6%), indwelling catheters (*n*=2; 0.5%), nasogastric tubes (*n*=2; 0.5%) and dialysis (*n*=3; 0.77%). No metabolic disorders, such as diabetes, were recorded in association with infection.

Type of infections
------------------

Infections due to *Fusarium* were predominantly found to be superficial and subcutaneous (*n*=174; 44.8%), occurring on the skin (*n*=62; 16%), eyes (*n*=66; 17%) and nails (*n*=25; 6.4%). Deep infections involved bone, joint and lung (*n*=4; 1%), heart (*n*=3; 0.77%), and peritoneum (*n*=2; 0.5%). The sum of the invasive and disseminated cases was *n*=109 (28%), some of which were associated with fungemia (*n*= 25; 6.4%) or disseminated disease with brain abscesses (*n*=4; 1% [Table 2](#tbl2){ref-type="table"}).

Treatment
---------

An overview of the reported treatment of the cases of fusariosis is shown in [Table 3](#tbl3){ref-type="table"}. The most widely used antifungal agent was amphotericin B deoxycholate (*n*=198; 51%), followed by liposomal amphotericin B (*n*=45; 11.6%), voriconazole (*n*=42; 10.8%), 5-flucytosine (*n*=30; 7.7%), itraconazole (*n*=26; 6.7%), fluconazole (*n*=25; 6.4%) and ketoconazole (*n*=19; 4.9%).

The antifungal combinations used in treating fusariosis were given either as a two- or a three-drug combination. The most frequently used combination of two drugs was amphotericin B with voriconazole (*n*=24; 6%), followed by amphotericin B with 5-flucytosine (*n*=20; 5%), amphotericin B with ketoconazole (*n*=4; 1%) and amphotericin B with fluconazole (*n*=4; 1%). Other combinations were used in one or two cases. Triple combinations were used in 14 cases (*n*=14; 3.6%). In addition, surgery with antifungal treatment was used in 80 cases (20.6%). In addition to antifungal therapy and surgery, granulocyte transfusions or granulocyte--colony-stimulating factor transfusions were also used. Only seven isolates were associated with cases where no treatment was reported ([Table 3](#tbl3){ref-type="table"}). It was not possible to look at the changes in treatment over time, although the authors assume that azole treatments have increased while AmB has declined. With the current guidelines, liposomal amphotericin B (*n*=45; 11.6%) and voriconazole (*n*=42; 10.8%) are very similar according to the data from the reported cases.

Genetic analysis
----------------

A total of 127 *Fusarium* strains deposited in the CBS-KNAW collection were partially sequenced for *RPB2* and *TEF1*. The resulting two phylogenies yielded almost identical topologies with similar resolution. Almost all of the strains of known species in all complexes of *Fusarium* formed independent clades in each tree. A concatenated tree ([Figure 1](#fig1){ref-type="fig"}), including all major human--pathogenic complexes of *Fusarium*, was based on 146 selected sequences. The lengths of the generated sequence data were 795 and 507 bp for *RPB*2 and *TEF1*, respectively. Of the 1302 nucleotides sequenced, 720 (55.1%) were constant, 551 (42.2%) were parsimony informative and 576 (44.1%) were variably and parsimony non-informative using MEGA v. 6.2.^[@bib22]^ The combined tree was subdivided into several species complexes with high bootstrap values ([Figure 1](#fig1){ref-type="fig"}). Seven clades represented human opportunists within the *F. solani* species complex. Thirteen groups represented opportunistic species in the *F. fujikuroi* species complex with smaller human-associated clusters in the FOSC and to a lesser extent in the *F. chlamydosporum*, *F. polyphialidicum* (syn. *F. concolor*), *F. dimerum* and *F. incarnatum* species complexes. Strains CBS 454.97, CBS 483.94 and CBS 119850 were identified morphologically as *F. napiforme* but formed a separate cluster that was different from the three strains including the type strain of *F. napiforme* ([Figure 1](#fig1){ref-type="fig"}).

The AFLP profiles contained \~50−60 fragments in the range of 40−400 bp. The AFLP dendrogram comprised seven main clusters at the species complex level and additional subgroups within the main species clusters revealed genetic diversity within each species complex ([Figure 2](#fig2){ref-type="fig"}). However, the profiles did not significantly vary between the *F. solani* species complexes, such as *F. falciforme*, *F. keratoplasticum*, *F. lichenicola F. petroliphilum* and *F. pseudensiforme*, whereas there was significant AFLP variation between isolates within the *F. fujikuroi* species complex with separate profiles for each species and within other species complexes of *F. chlamydosporum*, *F. concolor*, *F. dimerum*, *F. incarnatum*-*equiseti* and *F. oxysporum*.

When comparing the AFLP clusters with the distribution of DNA sequence lineages, the groups were largely concordant. Groups 1−7 matched with previous identifications using *RPB2* and *TEF1* sequences. The *Fusarium concolor* species complex had one clinical subgroup, the *F. dimerum* species complex had two and the *Fusarium fujikuroi* species complex consisted of 16 clinical subgroups (15 named subgroups and 1 unnamed molecular lineage). The FIESC had a single clinical group, the FOSC was divided into two subgroups and the *F. solani* species complex comprised six named and one unnamed subgroup. The AFLP clusters and subclusters were almost identical to the sequencing identifications except for few strains within the *F. solani* species complex ([Figure 2](#fig2){ref-type="fig"}). The AFLP clusters were based on sequencing and the AFLP data generated from combinations of both dendrograms. In this study, similar clinical presentations of fusariosis were observed among the different AFLP species/genotypes, and there seems to be no relation between species and clinical presentation.

DISCUSSION
==========

The molecular epidemiology of *Fusarium* was investigated based on the genetic data generated for the *RPB2* and *TEF1* sequence analysis supplemented with the AFLP fingerprint data. The current study provides information on the locality, sources, species and geographic distribution in countries in which these fungi are common such as Brazil, China, Colombia, India, Mexico and the USA. One hundred and thirty *Fusarium* isolates, including eight type strains deposited at the CBS-KNAW collection, were included. Overall, there was a good correlation between sequence analysis and AFLP genotypes. To analyze the genetic relationships among the AFLP and sequencing genotypes, we used phylogenetic algorithms, which are commonly used to detect evidence of population subdivision and differentiation.^[@bib26]^

The second largest subunit of RNA polymerase (*RPB2*) and *TEF1* showed high resolution with high species-level resolution, distinguishing 29 *Fusarium* species including the most common clinically important *Fusarium* species *F. falciforme*, *F*. *keratoplasticum*, *F. oxysporum*, *F. petroliphilum*, *F. proliferatum* and *F. verticillioides*. Furthermore, these two loci were able to distinguish between other rare *Fusarium* species that cause a variety of infections ([Table 1](#tbl1){ref-type="table"}).

Although human opportunists were highlighted in many studies focusing on specific regions of the world and specific types of infections,^[@bib10],\ [@bib11],\ [@bib12],\ [@bib13],\ [@bib27],\ [@bib28],\ [@bib29],\ [@bib30],\ [@bib31],\ [@bib32],\ [@bib33],\ [@bib34]^ the 127 *Fusarium* strains from the current study were collected from 26 countries in six continents and included clinical and environmental strains and isolates from cold blooded animals. Of these, Australia, Brazil, India, Mexico and the USA were among the top 10 countries with the highest *Fusarium* infections based on clinical isolates in the CBS collection. Not surprisingly, 75 of the 127 patients from this study acquired their infection in one of these countries.

Previously, the majority of the clinically relevant *Fusarium* species were classified as two species complexes that in the past were referred to as a single species, *F. oxysporum* and *F. solani*.^[@bib35]^ Approximately 80% of human infections are caused by members of both species complexes,^[@bib36]^ but a significant share of infections is caused by the following novel species complex members: *F. dimerum, F. fujikuroi* and *F. incarnatum-equiseti*. Within the *F. solani* complex, there are six recognized species and one unnamed lineage (FSSC6) clinically involved in fusariosis ([Figure 1](#fig1){ref-type="fig"}). Of these species, *F. falciforme* (*n*=14/127 cases; 11%) was the dominant species in our study and mainly isolated from keratitis cases in Brazil, India and Mexico. Recently, Hassan *et al.*^[@bib13]^ showed that the majority of keratitis cases (*n*=46/65 cases; 70.7%) were *F. falciforme*. This species is emerging as one of the most virulent *Fusarium* species associated with fusariosis and keratitis.^[@bib15],\ [@bib36],\ [@bib37]^

In the 2005--2006 mycotic keratitis outbreaks in Southeast Asia and North America that were associated with a contact lens cleaning solution, *F. petroliphilum* and *F. keratoplasticum* were the most common species,^[@bib36]^ which is consistent with the current study. The AFLP genotypic variability was higher in the environmental species than in the clinical species. A potential explanation is that not all environmental genotypes are sufficiently adapted to the host tissue and are not selected or perhaps a sampling effect is involved. Zhang *et al.*^[@bib35]^ studied the *F. solani* species complex, specifically those species that cause infections in humans and plants, and concluded that clinical isolates often shared multi-locus haplotypes with isolates from different environmental sources, including hospital locations. An increase of fusariosis among immunosuppressed patients was noted in the bone marrow transplant unit and among patients with superficial infections in a hospital in Rio de Janeiro, Brazil.^[@bib38]^ These authors concluded that this increase might be due to airborne conidia circulating in this geographical region. Short *et al.*^[@bib36]^ concluded that there is no evidence that clinical isolates differ from those collected from other sources.

The large diversity of the FOSC is not completely resolved, and it is not yet known whether the species have one or several phylogenetic origins or whether a single species or a species complex is concerned. From a traditional taxonomic point of view, *F. oxysporum* isolates are differentiated from each other based on the pathogenicity as *formae speciales*, but this has been shown to be an unreliable approach.^[@bib8]^ In addition, the species delimitation was for the FOSC, and at least 26 sequence types within the complex were involved in human infections.^[@bib39]^ Our FOSC clinical isolates were distributed throughout the complex, although some clustering was found in the clade marked 'sequence type 33\', which is based on *TEF1* alone, and this sequence type is considered the most common clade that contains clinical *F. oxysporum* strains. The remaining species complexes of *F. chlamydosporum*, *F. concolor*, *F. dimerum* and *F. incarnatum-equiseti* form separate clusters in the highly resolved sequence-based maximum likelihood tree ([Figure 1](#fig1){ref-type="fig"}).

The FIESC compromises 28 phylogenetically distinct lineages,^[@bib34]^ and only 2 are named and mainly involved in human infections (*F. incarnatum* and *F. equiseti*).^[@bib40]^ Although several members of the FIESC were included in the CDC *Fusarium* keratitis outbreak investigations, these species have not yet been observed to occur in epidemics or cause outbreaks. Concerning geography, 51 clinical isolates were recovered from the United States, and this revealed that phylogenetically diverse human opportunists are well represented in North America.^[@bib40]^ In our study, three clinical *F. equiseti* strains originated from Mexico, and this might suggest that species of this complex are common in this region. The virulence of members of the FIESC has been ascribed to their production of type A and B trichothecene mycotoxins.^[@bib39]^

*F. dimerum* and *F. delphinoides* belong to the *F. dimerum* species complex, and both were isolated from superficial and disseminated infections.^[@bib15]^ In our data set, a supported clade of FDSC matching with the AFLP data mainly contained strains from India, and this might suggest a regional prevalence. *F. chlamydosporum* was reported in disseminated infections in patients with aplastic anemia and lymphocytic lymphoma from the United States^[@bib41],\ [@bib42]^ CBS 111770 (*F. concolor*) is the only clinical strain in the *F. concolor* species complex, and it was reported in a keratitis case from Spain.^[@bib43]^

By comparing AFLP and MLST data, *F. falciforme* and *F. keratoplasticum* appear to be widely distributed, at least in Mexico, North America, Europe and India, with dominancy in superficial infections, including keratitis and onychomycosis. *F. petroliphilum* is the second most diverse species and is also frequently involved in disseminated infections. *F. solani sensu stricto*, '5\', which was recently described as *Fusisporium* (*Fusarium*) *solani* (FSSC5),^[@bib7]^ contains strains such as CBS 135559, CBS 135564 and CBS 135565, which originate from Mexico, and shows significant occurrence in keratitis cases. This species was also recently reported in Asia (India and Qatar).^[@bib13],\ [@bib16]^ Given the large distances of identical strains occurring in many different countries, airborne distribution seems likely. However, the presence of *F. incarnatum, F. equiseti* and *F. chlamydosporum* in clinical samples from various infections in North America remains puzzling but can perhaps be explained by sampling effects.

As previously noted,^[@bib44]^ the *F. fujikuroi* complex contains the highest number of species. In our study, 15 supported clades were recognized in all of the molecular analyses ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). Nearly all of the clades have various geographic distributions. Within the *F. fujikuroi* species complex, *F. proliferatum* and *F. verticillioides* were the dominant clinically relevant species, having a global distribution and dominating in disseminated infections. *F. sacchari* is the second most prevalent species and was often isolated from keratitis restricted to India. Although *F. nygamai* and *F. napiforme* are the most multidrug-resistant species within the *F. fujikuroi* complex,^[@bib45]^ their presence in human infections is rare. *F. acutatum* was reported from nail infections in four cases in Qatar, showed a low degree of variability and has been suggested to be clonal.^[@bib16]^ These results emphasize that *F. acutatum* is an emerging human opportunist, which thus far was only detected in Asia. Sequence analysis of *RPB2* and *TEF1,* and AFLP showed that the strains CBS 119850, CBS 483.94 and CBS 454.97 were nested within the *F. fujikuroi* complex and close to *F. nygamai* and *F. andiyazi*, forming a well-supported monophyletic branch suggestive of a novel species.

Deep fusariosis is rare in healthy individuals; a single brain infection has been reported.^[@bib46]^ Local infections may occur after a direct inoculation or tissue breakdown by trauma or the entrance of foreign bodies. The treatment of superficial infections is usually successful and requires surgery, the removal of the foreign body and antifungal therapy. The most important risk factors for severe fusariosis are prolonged neutropenia and T-cell immunodeficiency in patients suffering from a hematologic malignancy. *Fusarium* infections in the majority of these cases were due to neutropenia. Furthermore, in solid organ transplant recipients and cancer patients with neutropenia, infections due to *Fusarium* spp. increased and led to disseminated infection. Patients develop painful skin lesions, which vary from papules to nodules with or without central necrosis.^[@bib47]^ In the majority of disseminated infections, secondary skin lesions led to a diagnosis in \>50% of the patients and preceded fungemia by \~5 days.^[@bib48]^ In contrast to aspergillosis, fusariosis frequently shows positive blood cultures because *Fusarium* conidia are hydrophilic and allow dissemination.^[@bib47]^ Comparing fusariosis with mucormycosis,^[@bib49]^ solid tumors and diabetes do not seem to be important risk factors. Only 17 (4.8%) cases were found in patients with solid tumors, and seven infections were reported in patients with diabetes mellitus. No underlying conditions were observed in 20 (5%) of the cases.

*Fusarium* treatment depends on the site of infection. Surgery with antifungals was used in 80 cases (20.6%). Disseminated fusariosis in immunocompromised patients is usually treated with amphotericin B and voriconazole as the first-line therapy, which is suggested by recent guidelines.^[@bib50]^ In our literature review, most antifungal therapy was amphotericin B deoxycholate, followed by liposomal amphotericin B and voriconazole. The most commonly used combination is amphotericin B/voriconazole followed by amphotericin B/5-flucytosine. Triple combinations were used in 14 cases with different antifungals.

The major findings of the present study include the following: (i) human-associated fusaria were nested within seven species complexes (that is, *F. chlamydosporum*, *F. concolor*, *F. dimerum*, *F. fujikuroi*, *F. incarnatum-equiseti*, *F. oxysporum* and *F. solani*), (ii) the three most common species presented in both the clinical and environmental groups are *F. falciforme* and *F. keratoplasticum* (members of *F. solani* species complex) followed by *F. oxysporum* (FOSC), (iii) most of the reported *Fusarium* species in this study were shared among the patients and the environment, and this might be due to the colonization of some patients with *Fusarium* isolates from the environment; hence, there is genetic similarity between the clinical and environmental isolates of the same *Fusarium* species, and (iv) the species distributions show some evidence of geographical clustering among some of the species studied, although the present study is limited by an over-representation of isolates from Mexico and India.
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![A phylogenetic tree resulting from the RAxML analysis for the *RPB2* and *TEF1* genes. The total alignment length is 1302 bp. A maximum-likelihood analysis was performed using RAxML with non-parametric bootstrapping using 1000 replicates. The numbers above the branches are bootstrap support values ≥0.70. The outgroup was the epitype (ET) strain of *F. dimerum* CBS 108944.](emi2016126f1){#fig1}

![Clustering of the amplified fragment length polymorphism banding pattern of *Fusarium* spp. combined with a sequence analysis of *RPB2* and *TEF1* constructed by Bionumerics v7.5 (Applied Maths). The dendrogram was generated using the Unweighted Pair Group Method with Arithmetic Mean algorithm.](emi2016126f2){#fig2}

###### Isolates of *Fusarium* included in this study that were used for the sequence analysis and amplified fragment length polymorphism analysis, except for six *RPB2* and *TEF1*, which were retrieved from GenBank

  **CBS number**       **Species name**       **Country**    **Source**                    **GenBank accession number**   
  -------------------- ---------------------- -------------- ----------------------------- ------------------------------ ----------
  CBS 130548           *F. acutatum*          Iran           Onychomycosis (Human)         KR071756                       KU604289
  CBS 113964           *F. acutatum*          Egypt          Environmental                 KR071759                       KU604290
  CBS 739.97           *F. acutatum*          India          Environmental                 KR071757                       KU604288
  CBS 401.97           *F. acutatum*          India          Environmental                 KR071755                       KU604287
  CBS 402.97           *F. acutatum*          India          Environmental                 KR071754                       KT154005
  CBS 118517           *F. ananatum*          South Africa   Environmental                 KR071761                       KU604273
  CBS 118518           *F. ananatum*          South Africa   Environmental                 KU711690                       KU604271
  CBS 118516           *F. ananatum*          South Africa   Environmental                 KR071760                       KU604269
  CBS 184.29           *F. ananatum*          Unknown        Environmental                 KR071762                       KU604272
  CBS 256.93           *F. andiyazi*          Cuba           Environmental                 KR071719                       KU604231
  CBS 119857           *F. andiyazi*          South Africa   Environmental                 KP662901                       KT154004
  CBS 737.97           *F. anthophilum*       Germany        Environmental                 KU711685                       KU604277
  CBS 222.76           *F. anthophilum*       Germany        Environmental                 KR071766                       KT154006
  CBS 119858           *F. anthophilum*       USA            Environmental                 KR071764                       KU604275
  CBS 119859           *F. anthophilum*       New Zealand    Environmental                 KR071765                       KU604279
  CBS 961.87           *F. concolor*          South Africa   Environmental                 KR071773                       KU604556
  CBS 676.94           *F. concolor*          South Africa   Environmental                 KR071774                       KU604237
  CBS 111770           *F. concolor*          Spain          Keratitis (Human)             KU711719                       KU604323
  C26                  *F. delphinoides*      India          Keratitis (Human)             KU711775                       KU604380
  C52                  *F. dimerum*           India          Keratitis (Human)             KU711776                       KU604381
  CBS 135550           *F. equiseti*          Mexico         Keratitis (Human)             KU711721                       KU604324
  CBS 135552           *F. equiseti*          Mexico         Keratitis (Human)             KU711723                       KU604325
  CBS 135553           *F. equiseti*          Mexico         Keratitis (Human)             KU711722                       KU604326
  CBS 135532           *F. falciforme*        Mexico         Keratitis (Human)             KU711737                       KU604356
  CBS 135533           *F. falciforme*        Mexico         Keratitis (Human)             KU711738                       KU604362
  CBS 135521           *F. falciforme*        Mexico         Keratitis (Human)             KU711733                       KU604357
  CBS 135520           *F. falciforme*        Mexico         Keratitis (Human)             KU711732                       KU604363
  CBS 135526           *F. falciforme*        Mexico         Keratitis (Human)             KU711734                       KU604366
  CBS 135524           *F. falciforme*        Mexico         Keratitis (Human)             KU711730                       KU604358
  CBS 135525           *F. falciforme*        Mexico         Keratitis (Human)             KU711731                       KU604359
  CBS 135558           *F. falciforme*        Mexico         Keratitis (Human)             KU711736                       KU604368
  CBS 135559           *F. falciforme*        Mexico         Keratitis (Human)             KU711735                       KU604369
  CBS 135513           *F. falciforme*        Mexico         Onychomycosis (Human)         KU711724                       KU604360
  CBS 135512           *F. falciforme*        Mexico         Onychomycosis (Human)         KM401894                       KM401892
  C256                 *F. falciforme*        India          Keratitis (Human)             KU711725                       KU604361
  CBS 135522           *F. falciforme*        Mexico         Keratitis (Human)             KU711726                       KU604364
  CBS 135523           *F. falciforme*        Mexico         Keratitis (Human)             KU711727                       KU604367
  CBS 125177           *F. ficicrescens*      Iran           Environmental                 KP662898                       KT154001
  CBS 125178           *F. ficicrescens*      Iran           Environmental                 KP662899                       KT154002
  CBS 125181           *F. ficicrescens*      Iran           Environmental                 KP662900                       KT154003
  CBS 449.95           *F. fujikuroi*         France         Environmental                 KR071742                       KU604259
  CBS 257.52           *F. fujikuroi*         Japan          Environmental                 KU711678                       KU604257
  CBS 262.54           *F. fujikuroi*         India          Environmental                 KR071744                       KU604256
  CBS 221.76           *F. fujikuroi*         Taiwan         Environmental                 KR071741                       KU604255
  CBS 130402           *F. fujikuroi*         USA            Human skin (Human)            KU711677                       KU604261
  CBS 121864           *F. fujikuroi*         USA            Environmental                 KR071743                       KU604258
  CBS 119855           *F. fujikuroi*         USA            Environmental                 KU711679                       KU604260
  CBS 454.97           *Fusarium* sp          Sudan          Environmental                 KU711697                       KU604266
  CBS 483.94           *Fusarium* sp          Australia      Environmental                 KU711698                       KU604267
  CBS 119850           *Fusarium* sp          Australia      Environmental                 KU711699                       KU604268
  CBS 135528           *F. keratoplasticum*   Mexico         Keratitis (Human)             KU711743                       KU604338
  dH22044/F610         *F. keratoplasticum*   Netherlands    Keratitis (Human)             KU711744                       KU604339
  CBS 135527           *F. keratoplasticum*   Mexico         Keratitis (Human)             KU711742                       KU604340
  CBS 135531           *F. keratoplasticum*   Mexico         Eumycetoma (Human)            KU711741                       KU604353
  CBS 135530           *F. keratoplasticum*   Mexico         Eumycetoma (Human)            KU711740                       KU604352
  CBS 135529           *F. keratoplasticum*   Mexico         Keratitis (Human)             KU711739                       KU604354
                                                                                                                           
  dH21918/F605         *F. keratoplasticum*   Netherlands    Nail infection (Human)        KU711746                       KU604344
  dH22043/F609         *F. keratoplasticum*   Netherlands    Foot infection (Human)        KU711747                       KU604341
  CBS 748.97           *F. napiforme*         Namibia        Environmental                 KR071712                       KU604233
  CBS 674.94           *F. napiforme*         Australia      Environmental                 KR071713                       KU604239
  CBS 135139           *F. napiforme*         India          Keratitis (Human)             KR071717                       KU604234
  CBS 135140           *F. napiforme*         India          Keratitis (Human)             KR071714                       KU604235
  dH 21772/F602        *F. oxysporum*         Netherlands    Nail infection (Human)        KU711714                       KU604318
  dH22047/F611         *F. oxysporum*         Netherlands    Nail infection (Human)        KU711711                       KU604314
  CBS 135560           *F. oxysporum*         Mexico         Keratitis (Human)             KU711709                       KU604317
  CBS 135561           *F. oxysporum*         Mexico         Keratitis (Human)             KU711710                       KU604316
  CBS 463.91           *F. oxysporum*         Germany        Nail infections (Human)       KU711712                       KU604315
  CBS 135515           *F. petroliphilum*     Mexico         Keratitis (Human)             KU711760                       KU604336
  CBS 135518           *F. petroliphilum*     Mexico         Keratitis (Human)             KU711762                       KU604334
  CBS 135519           *F. petroliphilum*     Mexico         Keratitis (Human)             KU711765                       KU604331
  CBS 135535           *F. petroliphilum*     Mexico         Keratitis (Human)             KU711761                       KU604335
  CBS 135514           *F. petroliphilum*     Mexico         Mycotic keratitis (Human)     KU711767                       KU604330
  CBS 187.34           *F. phyllophilum*      UK             Environmental                 KU711680                       KU604300
  CBS 246.61           *F. phyllophilum*      Germany        Environmental                 KU711681                       KU604301
  CBS 480.77           *F. proliferatum*      Netherlands    Environmental                 KR071736                       KU604245
  CBS 182.32           *F. proliferatum*      USA            Environmental                 KR071734                       KU604246
  CBS 183.29           *F. proliferatum*      Japan          Environmental                 KR071735                       KU604242
  CBS 184.33           *F. proliferatum*      Guyana         Environmental                 KR071737                       KU604244
  CBS 125014           *F. proliferatum*      USA            Deep infection (Human)        KR071738                       KU604243
  CBS 131391           *F. proliferatum*      Australia      Environmental                 KR071732                       KU604247
  CBS 133030           *F. proliferatum*      Iran           Onycomycosis (Human)          KR071733                       KU604248
  CBS 135547           *F. proliferatum*      Mexico         Keratitis (Human)             KU711675                       KU604254
  CBS 135549           *F. proliferatum*      Mexico         Keratitis (Human)             KU711676                       KU604253
  CBS 116324           *F. proliferatum*      Spain          Keratitis (Human)             KR071731                       KU604249
  CBS 130179           *F. proliferatum*      USA            Deep infection (Human)        KR071739                       KU604241
  dH23807/CBS 132761   *F. proliferatum*      France         Deep infection (Human)        KU711673                       KU604250
  dH23808/CBS 132762   *F. proliferatum*      France         Deep infection (Human)        KU711674                       KU604252
  dH23810/CBS 132764   *F. proliferatum*      Unknown        Environmental                 KU711672                       KU604251
  CBS 135554           *F. pseudensiforme*    Mexico         Eumycetoma (Human)            KU711769                       KU604377
  CBS 135555           *F. pseudensiforme*    Mexico         Eumycetoma (Human)            KU711770                       KU604375
  CBS 135557           *F. pseudensiforme*    Mexico         Keratitis (Human)             KU711771                       KU604376
  CBS 135142           *F. sacchari*          India          Corneal ulcer (Human)         KR071749                       KU604304
  CBS 135143           *F. sacchari*          India          Corneal ulcer (Human)         KR071748                       KU604307
  CBS 135144           *F. sacchari*          India          Corneal ulcer (Human)         KR071750                       KU604305
  CBS 135145           *F. sacchari*          India          Corneal ulcer (Human)         KR071751                       KU604306
  CBS 223.76           *F. sacchari*          India          Environmental                 KU711669                       KU604309
  CBS 134.73           *F. sacchari*          Guyana         Environmental                 KR071753                       KU604303
  CBS 131369           *F. sacchari*          Australia      Environmental                 KR071752                       KU604302
  CBS 121683           *F. sacchari*          India          Endophthalmitis (Human)       KR071747                       KU604308
  CBS 135563           *F. solani* (FSSC5)    Mexico         Hyalohyphomycosis (Human)     KU711758                       KU604372
  CBS 135564           *F. solani* (FSSC5)    Mexico         Hyalohyphomycosis (Human)     KU711759                       KU604373
  CBS 135565           *F. solani* (FSSC5)    Mexico         Hyalohyphomycosis             KU711757                       KU604371
  CBS 119831           *F. subglutinans*      New Guinea     Environmental                 KR071769                       KU604281
  CBS 747.97           *F. subglutinans*      USA            Environmental                 KU711691                       KU604280
  CBS 135538           *F. temperatum*        Mexico         Pulmonary infection (Human)   KF956082                       KU604283
  CBS 135539           *F. temperatum*        Mexico         Pulmonary infection (Human)   KF956083                       KU604286
  CBS 135540           *F. temperatum*        Mexico         Keratitis (Human)             KF956084                       KU604285
  CBS 135541           *F. temperatum*        Mexico         Keratitis (Human)             KF956085                       KU604284
  CBS 776.96           *F. thapsinum*         USA            Environmental                 KR071726                       KU604294
  CBS 733.97           *F. thapsinum*         South Africa   Environmental                 KR071730                       KU604299
  CBS 130176           *F. thapsinum*         Italy          Human mycetoma (Human)        KR071727                       KU604298
  CBS 119833           *F. thapsinum*         USA            Environmental                 KU711717                       KU604297
  CBS 109077           *F. thapsinum*         Ethiopia       Environmental                 KR071728                       KU604295
  CBS 114579           *F. verticillioides*   Austria        Sputum (Human)                KU711696                       KU604220
  CBS 115135           *F. verticillioides*   Sweden         Deep infection (Human)        KR071710                       KU604217
  CBS 131390           *F. verticillioides*   Australia      Environmental                 KR071711                       KU604225
  CBS 116665           *F. verticillioides*   Unknown        Environmental                 KR071705                       KU604221
  CBS 135542           *F. verticillioides*   Mexico         Onychomycosis (Human)         KU711693                       KU604227
  CBS 135543           *F. verticillioides*   Mexico         Onychomycosis (Human)         KU711694                       KU604228
  CBS 135545           *F. verticillioides*   Mexico         Onychomycosis (Human)         KX584417                       KU604229
  CBS 576.78           *F. verticillioides*   Russia         Environmental                 KR071703                       KU604216
  CBS 579.78           *F. verticillioides*   USA            Ulcer of left leg (Human)     KR071706                       KU604223
  CBS 122159           *F. verticillioides*   Spain          Environmental                 KR071707                       KU604224
  CBS 123670           *F. verticillioides*   USA            Environmental                 KR071708                       KU604222
  CBS 102699           *F. verticillioides*   Germany        Abdominal drainage (Human)    KR071704                       KU604218
  CBS 108922           *F. verticillioides*   Germany        Urine (Human)                 KR071709                       KU604219
  CBS 131389           *F. verticillioides*   Australia      Environmental                 KU711695                       KU604226

###### Characteristics of 388 patients with fusariosis and literature cases from 1958 until 2015

  **Characteristic**                                            **Number of patients**
  ------------------------------------------------------------- -----------------------------------
  Total                                                         388
  Age, years (range)                                            3 months−82 years
  Sex, M:F:unknown                                              253 (65.3%):125 (32.2%):10 (2.5%)
                                                                
  *Underlying condition*                                        
   Transplantation                                              
    Liver                                                       5 (1.2%)
    Lung                                                        4 (1%)
    Bone morrow                                                 29 (7.5%)
    Multivisceral (stomach, duodenum, pancreas and intestine)   1 (0.25%) 7 (1.8%)
    Kidney                                                      3 (0.77%)
    Heart                                                       4 (1%)
    Stem cells                                                  38 (9.8%)
   Trauma/burns                                                 27 (7%)
   Foreign body                                                 18 (4.6%)
    Contact lens                                                4 (1%)
    Catheter                                                    2 (0.5%)
    Graft                                                       3 (0.77%)
    Nasogastric tube                                            3 (0.77%)
    Dialysis                                                    4 (1%)
   Cancer                                                        
    Hematologic                                                 122 (31.4%)
    Solid organ                                                 17 (4.8%)
   Medication                                                    
    Antibiotics                                                 140 (36%)
    Steroids                                                    34 (8.8%)
   No                                                           20 (5%)
                                                                 
  *Site of infection*                                           
   Superficial                                                   
    Skin                                                        62 (16%)
    Eye                                                         66 (17%)
    Nail                                                        25 (6.44)
    Bone                                                        4 (1%)
    Joint                                                       4 (1%)
    Lung                                                        4 (1%)
    Endocarditis                                                3 (0.77%)
    Peritoneum                                                  2 (0.5%)
    Perinephric abscess                                         2 (0.5%)
   Disseminated                                                 109 (28%)
    Blood                                                       25 (6.4%)
    Brain                                                       4 (1%)

Abbreviations: female, F; male, M.

###### Treatment administered to 388 patients with fusariosis

  *Treatment*                                  
  -------------------------------------------- ------------
   *Primary treatment (one drug)*              
    Amphotericin B                              
     Deoxycholate                              198 (51%)
     Lipid/liposomal                           45 (11.6%)
    Voriconazole                               42 (10.8)
    Flucytosine                                30 (7.7%)
    Itraconazole                               26 (6.7%)
    Fluconazole                                25 (6.4%)
    Ketoconazole                               19 (4.9%)
    Rifampicin                                 13 (3.4)
    Posaconazole                               3 (0.77%)
    Terbinafine                                ---
    Natamycin                                  2 (0.5%)
    Surgery                                    80 (20.6%)
    G-CSF                                      25 (6.4%)
    G-Transfusion                              13 (3.4%)
    No therapy                                 7 (1.8%)
                                               
  * Combinations (two drugs)*                  
    Amphotericin B/voriconazole                24 (6%)
    Amphotericin B/5-flucytosine               20 (5%)
    Amphotericin B/ketoconazole                4 (1%)
    Amphotericin B/fluconazole                 4 (1%)
    Amphotericin B/posaconazole                2 (0.5%)
    Amphotericin B/itraconazole                2 (0.5%)
    Amphotericin B/caspofungin                 1 (0.26%)
    Voriconazole/caspofungin                   2 (0.5%)
    Voriconazole/anidulafungin                 1 (0.26%)
    Voriconazole/terbinafine                   1 (0.26%)
    Ketoconazole/terbinafine                   1 (0.26%)
    Ketoconazole/rifampicin                    1 (0.26%)
    Itraconazole/terbinafine                   2 (0.5%)
    Itraconazole/terbinafine                   1 (0.26%)
                                               
  * Combinations (three drugs)*                
    Amphotericin B/flucytosine/rifampicin      2 (0.5%)
    Amphotericin B/itraconazole/rifampicin     2 (0.5%)
    Amphotericin B/flucytosine/ketoconazole    2 (0.5%)
    Amphotericin B/fluconazole/voriconazole    2 (0.5%)
    Amphotericin B/fluconazole/itraconazole    1 (0.26%)
    Amphotericin B/itraconazole/voriconazole   1 (0.26%)
    Amphotericin B/flucytosine/itraconazole    1 (0.26%)
    Amphotericin B/fluconazole/rifampicin      1 (0.26%)
    Amphotericin B/voriconazole/micafungin     1 (0.26%)
    Amphotericin B/voriconazole/terbinafine    1 (0.26%)

Abbreviation: granulocyte--colony-stimulating factor, G-CSF.
